A shorter half-life and cesium radiation promise to make cesium-131 capsules harder on cancer and easier on the patient.
Developed by IsoRay Medical, Inc., with assistance from Pacific Northwest National Laboratory, this new FDA-approved treatment uses tiny capsules or seeds filled with a small dose of the radioactive isotope, cesium-131.
The capsules are implanted near or in the cancerous tumor, where x-rays emitted by the cesium damage the genetic material of the cancer cells, making it impossible for these cells to continue to grow and divide. With cesium-based brachytherapy (from the Greek prefix "brachy," meaning "close"), more power or dose is delivered to the tumor over a shorter time.
The Department of Energy's Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time.